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ABSTRACT
This study aims to describe and characterize incident HR-HPV infections and associated diseases in
HIV-infected women. 805 HIV-infected women enrolled in the VALHIDATE Study were screened and
followed-up for HPV by co-testing. Social, behavioral and health data were collected. HPV-DNA
positive samples were typed using a commercial kit or RFLP analysis. Conventional Pap-smears
were evaluated using the 2001 Bethesda System. The participants with abnormal cytological results
were referred for colposcopy. 565 HIV-infected women (median age: 43 years) were analysed, 40.9%
had >5 lifetime sexual partners, 77.2% contracted HIV through sexual intercourse, 93% were receiv-
ing antiretroviral treatment and 77.3% had undetectable HIV-RNA. The women underwent 1254
follow-ups (median follow-up: 33 months) for 1430.6 PersonYear-Follow-Up. 37.4% of baseline HPV-
negative women acquired incident HPV-infections, 69.6% of which were HR-HPVs. HPV-53 was the
most common HPV type detected (9.3%). 18.2% of women showed incident or progressive cytolo-
gical abnormalities (7.8% ASC-US, 9.7% LSIL and 0.6% HSIL) and colposcopy revealed CIN2 (N = 2),
CIN1 (N = 2) and VIN3 (N = 1). The preventable fraction of incident infections was 11.3%, 16.7%, and
35.2% for the 2v-4v-9v-HPV vaccines respectively (χ2 p < 0.0001). The overall burden of incident
lesions attributable to the vaccine types were 9.1% for 2v-, 14.5% for 4v- and 30.9% for 9v-vaccine.
High HPV incidence rates and high percentages of multiple HR-HPV infections were observed in a
cohort of HIV-infected women receiving effective antiretroviral treatment. Primary prevention stra-
tegies based on the new 9v-HPV vaccine may help to prevent incident infections and disease
progression in this cohort of women.
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Introduction
The lifetime probability of contracting High-Risk Human
Papillomavirus (HR-HPV) infections is approximately
70–75% in sexually active women1 and the risk of infec-
tion and progression toward invasive disease is influenced
by viral and host factors. The disease is currently con-
trolled through cytological and/or molecular screening
and primary vaccine prevention. Three types of HPV
vaccines are available: the 2-valent vaccine (Cervarix®,
GlaxoSmithKline biologicals), which protects against HR-
HPV types 16 and 18; 4-valent vaccine (Gardasil®, Merck,
Sanofi Pasteur MSD), which protects against HPV types 6,
11, 16 and 18; and 9-valent vaccine (Gardasil®9, Merck,
Sanofi Pasteur MSD), which protects against HPV types 6,
11, 16, 18, 31, 33, 45, 52, 58. Administrating HPV vaccine
to females who have not yet been exposed to the targeted
types of HPV is the most appropriate and cost-effective
strategy for protecting them against HPV infections and
related sequelae.2
In the general population, HR-HPV infection is considerably
higher in young people and decreases with age,3 yet no decline is
evident in women living with HIV/AIDS.4 For these women, the
overall risk of HR-HPV infection, the risk of infection with non
16/18 HR-HPV types and of multiple infections and disease
progression are significantly higher than for immunocompetent
age-matched women.5-7 However, even if the rates of HPV
infection are higher for women living with HIV/AIDS, it has
been reported that immunity induced by natural infection with
HR-HPV is not long-lasting and does not protect against future
re-infection with the same type.8
In 2010 we carried out a prospective cohort study (the
VALHIDATE Study)9 based on HPV and cytology co-testing
aimed at characterizing the molecular epidemiology of HPV
infections and associated diseases by comparing women at
high-risk of infection with a control group of women belong-
ing to the general population.
The aim of this study is to describe and characterize
incident HR-HPV infections in women living with HIV/
AIDS enrolled in the VALHIDATE Study and followed up
for 5 years and to verify the potential impact of HPV
vaccines in these women even if pre-exposed to several
HPV infections.
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Results
Baseline characteristics of the women enrolled
The median age of the HIV-infected women was 43 years
(IQR: 37-47y), most of whom were Italian (82.1%) with a
medium/high educational level (51.7%) and 45.3% were smo-
kers. 231 women (40.9%) declared to have had >5 lifetime
sexual partners and 71% declared one sexual partner in the
previous six months. 53% declared to have contracted at least
1 sexually transmitted infection in their lives. The women
mainly contracted HIV infection through sexual intercourse
(436/565, 77.2%) and had a median CD4+ count of 569.5
cells/µL. 93% were taking antiretroviral treatment and 77.3%
had undetectable HIV-RNA (< 37 copies/mL) (Table 1).
Baseline evaluation
At baseline evaluation, 485 (85.8%) women were NILM, while
ASC-US was diagnosed in 28 (5.0%), LSIL in 43 (7.6%), AGC
in 3 (0.5%), ASC-H in 2 (0.3%) and HSIL in 4 (0.7%). 44
histological analyses identified 2 cases of CIN3, 3 cases of
CIN2, 12 cases of CIN1 and 1 case of Vaginal Intraepithelial
Neoplasia-1 (VAIN-1) (Table 2).
Overall, at baseline 153 (27.1%; 95% CI: 23.5–31.0) women
were HPV-DNA positive and 127 (22.5%; 95% CI: 19.1–26.2)
were HR-HPV infected.
HPV infection and HPV typing at baseline and during the
follow-up period
285 HPV infections were identified in 153 HPV infected
women at baseline (mean 1.9 HPVs per woman, range 1–8).
Single infections were detected in 74 HPV-infected women
(48.4%) while multi-type infections (2 to 8 HPVs) in the other
79 HPV-infected women, 146 (51.2%) of which were sus-
tained by HPVs included in group-1, 63 (22.1%) in groups-
2A/2B and 76 (26.7%) in group-3, according to the IARC
classification10 (Figure 1).
The overall HR-HPV infection rate was 73.3% (209/285). The
most common HPV was HPV-16 (8.8%), followed by HPV-52
(7.7%), HPV-66 (7.0%), HPV-53 (6.7%) (Figure 1a). At baseline
the percentage of women infected with HPV-16 or HPV-18
alone or combined with other HPV types amounted to 20.3%,
while the rate of women with other HR-HPV types was 58.2%.
The research participants underwent 1254 follow-up visits
(mean 2.2 follow-ups per woman); median follow-up was
33 months (IQR: 20–40 months) for a total of 1430.6 PY-
FU. Overall, 702 HPV infections were detected among the 243
HPV positive women at the follow-up visits (mean 2.9 HPV
infections per woman). HPV-16 was the most commonly
found (11.1%), followed by HPV-66 (8.7%), HPV-52 (7.6%),
HPV-56 (6.6%), HPV-53 (6.6%) (Figure 1b). The overall HR-
HPV detection rate remained stable (74.2%).
Incident HPV infections and genital lesions
During follow-up, 154 (37.4%) of the 412 HPV women who
tested negative at baseline, developed an incident HPV infec-
tion (incidence rate 0.15 cases PY-FU). The distribution of
Table 1. Social, epidemiological and clinical characteristics of women at baseline
evaluation.
Characteristics of women enrolled N (%)
Country or continent of origin Italy 464 (82.1)
Africa 61 (10.8)
Asia 6 (1.1)
Central/South
America
17 (3.0)
Europe 17 (3.0)
Education Primary school 272 (48.1)
Secondary
school
244 (43.2)
Degree 48 (8.5)
Unknown 1 (0.2)
Smoking habits Smoker 256 (45.3)
Non smoker 197 (34.9)
Previous smoker 112 (19.8)
N of lifetime sexual partners 1 46 (8.1)
2–5 285 (50.4)
>5 231 (40.9)
Not known 3 (0.5)
N of sexual partners in the last
6 months
0 152 (26.9)
1 401 (71.0)
2–3 8 (1.4)
>3 1 (0.2)
Not known 3 (0.5)
History of Sexually Transmitted
Infections (STIs)
≥ 1 STI 300 (53.1)
No STI 260 (46.0)
Not known 5 (0.9)
Mode of HIV infection Sexual 436 (77.2)
Parenteral 124 (21.9)
Mother-to-child 5 (0.9)
CDC stage of HIV A 254 (45.0)
B 119 (21.0)
C 121 (21.4)
Not known 71 (12.6)
HIV viral load Undetectable 437 (77.3)
(< 37 copies/mL) 126 (22.3)
Detectable 2 (0.3)
(>37 copies/mL)
Not known
Currently taking Antiretroviral
treatment
Yes 525 (92.9)
Noa 40 (7.1)
Antiretroviral treatment line 1st 111 (19.6)
2nd 94 (16.6)
3rd 62 (11.0)
>3rd 251 (44.4)
Not known 47 (8.3)
Age (years): median (IQR) 43 (37–47)
Baseline CD4+: median cells/µL (IQR) 569.5 (409–770.8)
Nadir CD4+: median cells/µL (IQR) 200 (100–300)
HIV viral load: mean log copies/
mL (SD)
1.85 (0.83)
a38 patients (6.7%) were not on antiretroviral treatment according to the Italian
guidelines for antiretroviral treatment
Table 2. Cervical abnormalities at baseline evaluation and prevalence rate of
HPV infections among HIV-infected women.
Result N % (95%CI)
Cytology (N = 565) NILM 485 85.8 (82.6–88.6)
ASC-US 28 5.0 (3.4–7.2)
LSIL 43 7.6 (5.6–10.2)
AGC 3 0.5 (0.1–1.7)
ASC-H 2 0.3 (0.1–1.4)
HSIL 4 0.7 (0.2–1.9)
Histology (N = 44) Neg 21 47.7 (32.7–63.1)
CIN1 12 27.3 (15.5–43.0)
VAIN1 1 2.3 (0.1–13.5)
CIN2 3 6.8 (1.8–19.7)
CIN3 2 4.5 (0.8–16.7)
Inadequate 5 11.4 (4.3–25.4)
HPV (any type) (N = 565) Pos 153 27.1 (23.5–31.0)
HR-HPV (N = 565) Pos 127 22.5 (19.1–26.2)
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HPV types detected in these new infections are reported in
Figure 1c. HPV-53 was the most commonly found type (24
cases, 9.3%), followed by HPV-16 and HPV-66 (23 cases each,
8.9%), HPV-56 (19 cases, 7.0%), HPV-52 and HPV-31 (13
cases each, 5.0%). The overall incident HR-HPV infection rate
was 69.6%. HPV-16 or HPV-18 alone or combined with other
HPV types were found in 28 women (17.9%), while 90 women
(57.7%) had HR-HPV infections other than HPV-16 or 18.
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b - Number and proportion of HPV types detected during the follow up
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c - Number and proportion of HPV types detected in incident infections 
Figure 1. HPV types detected at baseline (a), during follow-up (b) and in incident infections (c) grouped according to the IARC classification. The genotypes included
in 2v-, 4v-, or 9-v-HPV vaccines are coloured blue and green.
HUMAN VACCINES & IMMUNOTHERAPEUTICS 3
The HPV type distribution between baseline evaluation
and that observed in incident infections showed the same
figures for the most commonly found HPV types and for
the proportion of HR-HPV infections.
Among the women with incident HPV infections, 28
(18.2%) presented an incident or progressive cytological
abnormality. Cytology progressed from NILM to ASC-US in
12 (7.8%) cases, while LSIL was found in 15 (9.7%) cases and
HSIL in 1 (0.6%) case. The colposcopy-guided cervical biop-
sies, carried out on 15 evaluable patients detected 2 cases of
CIN2, 2 cases of CIN1 and 1 case of Vulvar Intraepithelial
Neoplasia-3 (VIN3). The overall incidence rate of any grade
of abnormality was 0.03 cases/PY-FU and the incidence rate
of HG-SILs was 0.004 cases/PY-FU.
Vaccine-preventable incident HPV infections
The preventable fraction of all incident infections was 11.3%,
16.7%, and 35.2% for the 2v-4v-9v-vaccines respectively
(χ2 p < 0.0001).
154 women who tested HPV negative at baseline acquired an
HPV infection during the follow-up, thus being incident cases.
Of these, 24 (15.6%) cases could have been prevented by admin-
istering the 2v-vaccine, 30 (19.5%) by administering the 4v-
vaccine and 63 (40.9%) with the 9v-vaccine (χ2 p < 0.0001).
HPV typing carried out on the 28 patients with incident
cervical/vulvar abnormalities showed 60 HPV infections
(mean 2.1 infections per woman) whose distribution can be
seen in (Figure 2).
HR-HPVs were responsible for 70.9% of infections in LG-
SILs and 100% of infections in HG-SILs. The overall burden
of lesions attributable to the vaccine types was 9.1% for the
2v-vaccine, 14.5% for 4v-vaccine and 30.9% for 9v-vaccine.
The 9v-vaccine would have prevented 60% of the infections
detected in the incident HG-SILs.
Discussion
The baseline HR-HPV infection prevalence (22.5%; 95%CI
19.1–26.2) observed was in line with that reported by
Konopnicki et al.11 regarding a cohort of Belgian HIV-
infected women (23%; 95%CI 19.3–26.8). In both studies,
HIV infection was well controlled by antiretroviral treatments
with high baseline CD4 cell counts and with undetectable
HIV viremia.
Although well-controlled by antiretroviral treatment, the
HR-HPV infection prevalence was significantly higher than
that reported for the general population with normal cervical
cytology. In a meta-analysis, Bruni et al. reported a global
adjusted HPV prevalence of 11.7% (95%CI 11.6–11.7) and an
adjusted prevalence of 9.1% (95%CI 9.0–9.2) in women aged
35–44 years.12 It is well known that HIV-induced immune
deficiency is associated with increased incidence, long-term
persistence of HPV infection and increased risk of progres-
sion to precancers/cancers.13-17 However, this study showed
that even women receiving effective antiretroviral therapy
with high CD4 cells and a well-controlled HIV viremia are
at increased risk of infection, thus suggesting that the risk of
infection may be due to factors other than immune-
depression.
Indeed, although the risk of HR-HPV infections in the
general population decreases with age, a significant propor-
tion of incident infections was observed in our cohort of mid-
adult women with an infection rate of up to 0.15 cases/year
follow-up. These findings may be due to the reported strong
association between new sexual partners and HPV incidence
in older women18,19 and by the possible reactivation of latent
infections reported in cases of impaired immunity.20
Therefore, when primary vaccine prevention is unadvisable
due to the high baseline prevalence of infection, the high
incidence rate of new HPV infections associated with the
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Figure 2. Percentage of HPV types detected in 28 incident SILs (blue bars) and in 4 HSILs (red bars).
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worst outcomes even in presence of immune reconstitution
suggests that a vaccine prevention strategy might help to
prevent new infections in HIV infected women.
As already reported,15,21 HIV infected women have a differ-
ent HPV type distribution to that of the general population with
a high prevalence of infections and HSILs caused by HR-HPV
types other than HPV-16/HPV-18. The large number of multi-
ple-type HPV infections observed prevented us from making a
type-specific attribution of the cervical lesions in HIV infected
women due to the small number of events observed.
However, it is well known that the HPV-16 and HPV-18
prevalence rate increases with the severity of cervical abnormal-
ities and that these two types account for approximately 70% of
all cervical cancers in the general population worldwide.7
Although Clifford et al.7 found that HPV-16 is the most carcino-
genic type in HIV infected women, the association between
HPV-16/18 and cancer is less evident than that reported for
the general population. There is evidence that HPV-16 is less
affected by HIV immune-depression due to its innate ability to
elude immune control while other oncogenic HPVs are more
affected by impaired immunity. However, the decrease in the
percentages of pre-cancers and cancers associated with HPV-16
is limited: HPV-16 is however the most carcinogenic HPV type
worldwide even in HIV infected women with an associated
increased burden of non-HPV-16 types resulting in a shift of
the HSIL towards other oncogenic HPV types.21
These observations may affect the screening and prevention
strategies used for HIV infected women. Keller et al.22 sug-
gested that HIV-infected women may benefit from cervical
cancer co-testing using Pap and HR-HPV assays since HIV
infected women with negative cytology who test HPV-16 posi-
tive have a similar pre-cancer risk to those with LSIL cytology
and therefore warrant immediate colposcopy; repeat screening
in 1 year is recommended for other HR-HPV infections.
HPV vaccines have proved to be highly effective for pre-
venting cancer in the general population. Identifying the
appropriate vaccination strategy in middle-aged HIV-infected
individuals already exposed to multiple HPV infections seems
to be crucial. The high rates of newly-acquired HR-HPV
infections, different HPV type distributions and progressive
genital lesions in HIV infected women underline how a 2v- or
4v-vaccine directed against the two main carcinogenic HPV
types could result in shortfalls for these women. In fact, the
incident infections caused by HPV-16 and/or HPV-18
accounted for 11.3% of all the new HPV infections acquired
during the follow-up period. By including the infections sus-
tained by LR HPV-6/-11, the preventable fraction of infec-
tions with 4v-vaccine rose to 16.7% thus covering a limited
fraction of the HPV types affecting HIV-infected women.
More recently, the 9v-vaccine has included coverage against
five additional HR-HPVs.23 In this cohort, the preventable
fraction of incident infections with a 9v-vaccine rose to
35.2%. These observations suggest that the cost/effectiveness
of 9v-vaccine, which has already been evaluated for the gen-
eral population24,25 should be even more effective for HIV-
infected women. Although there is positive anticipation, the
limitation of this study is that the effectiveness of the 9v-
vaccine is only hypothetic, since it is based on the distribution
of HPV types in incident infections and lesions in this
middle-aged and partially-immunosuppressed population.
Further research is required to obtain evidence of vaccine
effectiveness in order to identify the best primary prevention
strategy for HPV-related cancers in adults living with HIV/
AIDS.
Material and methods
Study design
Among the 805 HIV-infected women enrolled in the
VALHIDATE Study, 565 (70.2%) were considered eligible for
the study as they had attended at least one follow-up visit. The
women were followed up for 5 years and were evaluated for
incident HR-HPV infections and HPV type characterization.
Social, behavioural and health data, as well as immune-virolo-
gical and antiretroviral treatment data observed at baseline
evaluation and follow-up visits were collected from the eCRF
(electronic Case Report Form) of the study protocol. Written
informed consent was required from all of the eligible female
participants enrolled in the VALHIDATE Study. The study was
approved by the L. Sacco Hospital ethical committees (R.n°174/
2010, 9 March 2010).
Pap cytology and HPV tests
As already reported in the Study protocol,9 the Pap-smear
samples were obtained using a cervical brush (Cytobrush Plus
MedscandW Medical AB, Sweden). The pap-smears were
evaluated by cytopathologists from the participating centres
in accordance with the 2001 Bethesda System terminology.26
According to cytology at baseline, the cases were classified as
NILM, Negative for Intraepithelial Lesion or Malignancy;
ASC-US, Abnormal Squamous Cells of Undetermined
Significance; ASC-H, Abnormal Squamous Cells cannot
exclude High-grade squamous intraepithelial lesion; AGC,
Atypical Glandular Cells; LSIL, Low-grade Squamous
Intraepithelial Lesion; HSIL, High-grade Squamous
Intraepithelial Lesion. Women with abnormal cytological
results underwent colposcopy and biopsy if required and
were followed up in accordance with Italian guidelines.27
Abnormal biopsy results were classified as Cervical
Intraepithelial Neoplasia (CIN) grade 1–3, adenocarcinoma
in situ or cancer.
Cytological ASC-H and HSIL and histological lesions grade
2 or more were referred as HG-SILs (High Grade Squamous
Intraepithelial Lesions). Cytological results of ASC-US, LSIL,
AGC and histological results of CIN1 were referred as LG-
SILs (Low Grade Squamous Intraepithelial Lesions).
The cervical brushes used for cytology were then immersed
in a PreservCyt® solution (ThinPrep® Pap Test, Hologic Italia
Srl) and tested for HPV-DNA with an in-house PCR.28 The
HPV-DNA positive samples underwent HPV typing carried
out with the reverse hybridization Inno-LiPA® HPV
Genotyping Extra (Fujirebio, Belgium) test, which is able to
identify 28 HPVs (HPV: 6, 11, 16, 18, 26, 31, 33, 35, 39, 40, 43,
44, 45, 51, 52, 53, 54, 56, 58, 59, 66, 68, 69, 70, 71, 73, 74, 82).
All HPV-DNA positive cervical samples found to be non-
typeable by the Inno-LiPA® test were subjected to the
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Restriction Fragment Length Polymorphism (RFLP) analysis
which identifies all types of the High-Risk-clade (HR-clade)
and Low-Risk (LR) types of the alpha genus according to the
2011 IARC classification.10 The oncogenic potential of HPV
types depends on their association with disease malignancy.
The HR-clade includes HPV types 16, 18, 31, 33, 35, 39, 45,
51, 52, 56, 58, 59, classified in group-1 as “human carcino-
gens” and groups-2A (HPV 68) and −2B (HPV types 26, 30
34, 53, 66, 67, 69, 70, 73, 82, 83, 97) which include types that
are “probably carcinogenic to humans” and “possibly carcino-
genic to humans” respectively. The LR types in group-3 are
not classifiable as human carcinogens.
Follow-up
Regardless of the Pap result, a 6-month screening interval was
established for HIV-positive women with a CD4 cell counts
< 200 cells/µL and a yearly screening interval for those with
CD4 cell counts >200 cell/µL.
Statistical analysis and end-points
The end-points of the analysis were the incident HPV infections
from HR-HPV types in women with baseline HPV negative
results as well as incident abnormal cytological results.
Descriptive statistics [mean±Standard Deviation (SD) or
median and InterQuartile Range (IQR)] were used to describe
demographic, behavioural, epidemiological and clinical/
immunological characteristics of the study population.
We evaluated the type distribution of incident infections,
the role of specific risk factors for incident infections and
cytological abnormalities; the incidence rate was expressed
as Person-Years-of-Follow-Up (PY-FU). PY rates were calcu-
lated using all participants who were not positive for that
specific type at baseline as denominator.
Univariate logistic regression analyses were performed to
calculate the Odds Ratios (OR) and 95% Confidence Interval
(95%CI) of the association between the selected variables and
outcomes. The dependent variables were the incident HPV
infections and cytological abnormalities. All of the reported
P-values are two-sided; the data were analysed using
GraphPad Prism v5.00 (GraphPad Software, San Diego
California USA, www.graphpad.com).
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